Marvin Chang, MD
Pain Medicine · Sugar Land, TXNPI 1518910769
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,374 of the $10,740 with a category attached, or 68.7%. 30 manufacturers reported payments, led by Medtronic at 40.4% of the total. Reporting peaked in 2019 at $3,324 and has fallen 71.6% since, to $942 in 2025.
Across 233 payments — averaging $46.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Abbott$2K
- Nevro Corp.$1K
- Nalu Medical, Inc.$1K
- Scilex Pharmaceuticals Inc.$315
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$268
- plus $2K from 24 others
Across 30 payments — averaging $9852.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$296K
What the payments were for
- Speaking & faculty fees$1,0009%
- Travel & lodging$2,28921%
- Food & beverage$7,37469%
- Education$781%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(3 entities) | 38 | $4,340 |
| Abbott | 48 | $1,681 |
| Nevro Corp. | 31 | $1,202 |
| Nalu Medical, Inc. | 10 | $1,050 |
| Scilex Pharmaceuticals Inc. | 20 | $315 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $268 |
| Collegium Pharmaceutical, Inc. | 18 | $245 |
| Boston Scientific | 4 | $243 |
| Si-bone, Inc. | 3 | $233 |
| Globus Medical | 5 | $161 |
| Amgen(2 entities) | 8 | $158 |
| Painteq LLC | 4 | $115 |
| Avanos Medical | 1 | $112 |
| Nexxt Spine LLC | 1 | $90 |
| Pfizer | 4 | $71 |
| Assertio Therapeutics, Inc. | 4 | $61 |
| Hikma Pharmaceuticals USA | 3 | $56 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $43 |
| IBSA Pharma Inc. | 3 | $42 |
| Vertiflex, Inc. | 1 | $39 |
| Biodelivery Sciences International, Inc. | 2 | $39 |
| Arbor Pharmaceuticals, Inc. | 2 | $28 |
| Fujifilm Sonosite, Inc. | 1 | $28 |
| Biotissue Holdings Inc. | 1 | $24 |
| Electronic Waveform Lab, Inc. | 1 | $23 |
| GRT US Holding, Inc. | 1 | $22 |
| Zyla Life Sciences, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Relievant Medsystems, Inc. | 1 | $13 |
| Shionogi Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,740 in reported general payments places this provider in the 75th percentile of 583 pain medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PercocetOxycodone Hcl/Acetaminophen | 12 | $43,825 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,634 | $43,126 |
| MovantikNaloxegol Oxalate | 68 | $25,307 |
| BelbucaBuprenorphine Hcl | 54 | $23,621 |
| OxycontinOxycodone Hcl | 26 | $22,759 |
| Xtampza ErOxycodone Myristate | 24 | $14,205 |
| Pregabalin | 666 | $12,461 |
| Diclofenac Sodium | 63 | $11,790 |
| Tramadol Hcl ErTramadol Hcl | 206 | $11,430 |
| Lidocaine | 125 | $9,550 |
| Gabapentin | 752 | $9,487 |
| ZtlidoLidocaine | 24 | $8,736 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 373 | $7,954 |
| Oxycodone Hcl | 238 | $4,575 |
| Buprenorphine | 19 | $4,421 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $245 | $37,82778 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $315 | $8,73624 claims |
| Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate | $56 | $7,099103 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 583 pain medicine providers in Texas.
Other pain medicine in Sugar Land
- Candice BurnetteSugar Land$265K
- Melissa MurphyGrapevine$653K
- Shiraz YazdaniLubbock$514K
- Aaron CalodneyTyler$296K
- Ashley Bailey-ClassenFort Worth$244K
- Grant ChenHouston$175K
- Gunjan PatelHouston$166K
- Anthony BergRockwall$165K
- Puneet SayalCorpus Christi$153K
- Eduardo GarciaWebster$147K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.